FMP
NASDAQ
3.19 USD
0.11 (3.45%)
Dr. Kristin Yarema Ph.D.
Healthcare
Biotechnology
https://www.poseida.com
NASDAQ
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD...
0001661460
US73730P1084
73730P108
9390 Towne Centre Drive
858 779 3100
US
330
Jul 10, 2020
0001661460
NASDAQ
Biotechnology
Healthcare
73730P108
US73730P1084
US
3.19
0.39
743.56k
307.8M
-
1.54-4.27
-0.01
-
-
-
-
-2.33
-
https://www.poseida.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.